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Edited by Lukas HuberAbstract Tumour necrosis factor receptor 1 (TNFR1) plays a
critical role in host defence and inﬂammation. We have identiﬁed
a membrane proximal region (aa 218–324) of TNFR1 that
restricts surface expression. This was prompted by comparing
the dominant-negative properties of a C-terminal truncation of
TNFR1 with a point mutant that prevents signalling. C-terminal
truncation (aa 218–426) generates a better dominant-negative
TNFR1 mutant than inactivation of the death domain by point
mutation. The increased dominant-negative activity correlates
with increased cell surface expression. The membrane proximal
region is the most important region of the receptor for restricting
expression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumour necrosis factor receptor 1 (TNFR1/CD120a) is a
death-domain (DD) containing receptor and one of two re-
ceptors for the cytokine TNFa [1]. It is the high aﬃnity re-
ceptor for soluble TNFa and is predominantly responsible for
the eﬀects of TNFa even when the other receptor, TNFR2
(CD120b), is present [2–4]. TNFa signalling plays a critical
role in host defence, proliferation, apoptosis, inﬂammation
and diﬀerentiation [5].
The extracellular domain of TNFR1 is involved in the for-
mation of a pre-ligand oligomeric receptor complex and in TNF
binding. TNF binding to TNFR1 activates downstream sig-
nalling pathways via a number of adapter proteins, which bind
to the cytoplasmic domain of TNFR1 [6]. The DD (aa 320–415)
[7] (Fig. 1A) is able to recruit the adapter proteins, TNFR DD
protein [8], Fas-associated DD protein [9], and the serine/thre-
onine kinase, receptor RIP [10]. The DD is essential for the ac-
tivation of the nuclear factor-jB (NF-jB) pathway and
activation of the apoptotic caspase cascade.TheC-terminus also
contains sequenceswhich bind the factor associatedwith neutral* Corresponding author. Fax: +44-2920745003.
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protein, growth receptor bound 2 (Grb2, aa 237–240) [12]. The
FAN-binding sequence alone is required for the activation of the
neutral sphingomyelinase [11] and, together with the Grb2-in-
teracting sequence, for activation of the c-Raf-1 kinase [12].
This study initially investigated TNFR1 dominant negatives
for use as a research tool. Mutants were generated by changing
speciﬁc amino acids or by deletion of the adapter protein-
binding domains, and their signalling and dominant-negative
properties were assessed by transient transfection of the Eli-BL
B-cell line. We show that deletion of the TNFR1 cytoplasmic
domain generates the most eﬃcient TNFR1 dominant nega-
tive. Furthermore, this mutant displayed an extremely high cell
surface expression when compared to wild type (Wt) or point
mutated TNFR1. A region negatively regulating TNFR1 cell
surface expression was mapped to the membrane proximal
region of the cytoplasmic domain.2. Materials and methods
2.1. Cell lines
Eli-BL [13] and DG75 [14] B-cell lymphoma cell lines were cultured
in RPMI 1640 medium supplemented with 10% foetal calf serum and
200 U/ml penicillin and 200 mg/ml streptomycin antibiotics and
maintained at 37 C in a humidiﬁed atmosphere containing 5% CO2.
Basal production of TNFa was determined for both cell lines by
ELISA (Duoset kit, R&D Systems) and was found to be <20 pg/ml.
This was in agreement with previous values determined for Eli-BL and
other BL lines [20].
2.2. Plasmids
The vector pTARGET-TNFR1 Wt (provided by Dr. Michael Le-
nardo, National Institutes of Health, Bethesda, USA [15]) was used to
amplify the entire human TNFR1 coding region and shorter se-
quences, which were cloned into the pcDNA3.1–V5/His directional
TOPO cloning vector (Invitrogen). The common forward primer 50
CACCATGGGCCT- CCACCGTGCC 30 was used with the following
reverse primers: 50 TCTGAGAAGACTGGGCGCGG 30, 50 AATG-
GAGTAGAGCTTGGAC 30, 50 ATCAGTGTCTAGGCTCTG 30, 50
GCCCAGCAGGTCCATGTCG 30, 50 AAGCG- CCTCCTCGATG-
TCC 30 and 50 ACTGGGCGCGGGGGCGAG 30 to generate the
TNFR1 Wt, D218, D325, D403, D413 and D424 constructs, respec-
tively. The TNFR1 DFAN, AA and DAA mutants were generated
from TNFR1 Wt, using the Quikchange site-directed mutagenesis kit
(Stratagene), using the following primers; 50 CCCAACCCCCTTCC-
ACAGAGCCTAG 30 and its reverse complement (DFAN), and
50CGCTGGA AGGAAGCCGTGGCGCGCCTAGGGCTGAGC 30
and its reverse complement (AA). The 3Enh.jB-ConALuc reporter
(3Enh-Luc) contains three tandem repeats of the NF-jB binding sites
from the Igj promoter upstream of a minimal conalbumin promoterblished by Elsevier B.V. All rights reserved.
Fig. 2. (A) NF-jB activation by TNFR1 adapter protein-binding do-
main mutants. Eli-BL cells were transiently transfected with 3 lg NF-
jB luciferase reporter, 2 lg EGFP-N1 and 6 lg of each TNFR1
construct. Transfections were split into two. Sixteen hours post-
transfection, one half was mock stimulated and the other stimulated
with TNFa (10 ng/ml). After 8 h, luciferase activity was assayed. The
results are shown as fold-induction of NF-jB activity, calculated by
division of the raw value from the TNFa-stimulated well by the mock
stimulated well, for each transfection. The results are mean, and
standard error of at least three independent experiments. (B) TNFR1
D218 is a more eﬃcient dominant negative than TNFR1 AA. Eli-BL
Fig. 1. (A) Schematic representation of TNFR1 domains and signal-
ling pathways. (B) Panel of TNFR1 mutants utilised, showing the
mutations and aﬀected domains.
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(EGFP), pEGFP-N1, was purchased from Clontech.
2.3. Gene transfection and luciferase reporter assay
Up to 107 cells in 0.5 ml RPMI medium buﬀered with 100 mM
HEPES, pH 7.2, were transfected using a Bio-Rad Genepulser II
electroporator (280 V/950 lF for Eli-BL; 270 V/950 lF for DG75). The
cells were seeded in fresh growth medium. Transfection eﬃciency was
typically 5–20% for Eli-BL and 40–50% for DG75. Transfected cells
were either mock-stimulated with growth medium or stimulated with
10 ng/ml TNFa (purchased from R&D Systems), 16 h post-transfec-
tion. Luciferase activity was measured 8 h after stimulation with
TNFa, exactly as described previously [17].
2.4. Detection of cell surface TNFR1 expression (CD120a) by ﬂow
cytometry
Cell surface expression of TNFR1 in the transfected cell population
was assayed by ﬂow cytometry of immunoﬂuorescent staining. Cells,
harvested 24 h after transfection, were stained with anti-human TNFR1
mouse monoclonal antibody (Ab-1, Oncogene research products) or an
IgG1 isotype control antibody, followed by a rabbit anti-mouse phy-
coerytherin (PE)-conjugated secondary Fab fragment (Dako). Trans-
fected cells were marked by the expression of cotransfected EGFP-N1
plasmid and were gated for analysis of TNFR1 staining.cells were transiently transfected with 3 lg NF-jB luciferase reporter, 2
lg EGFP-N1, 6 lg TNFR1 wild type, and increasing amounts of
TNFR1 AA (circles) or D218 (squares). (Total DNA amount kept
constant at 21 lg, by addition of appropriate amounts of empty vec-
tor.) Transfections were split into two and 16 h post-transfection one
half was mock stimulated (white-ﬁlled) and the other stimulated with
10 ng/ml TNFa (black-ﬁlled). After 8 h, luciferase activity was assayed.
The results are shown as % maximal luciferase activity within each
experiment and are mean and standard error of three independent
experiments.3. Results
3.1. Generation of human TNFR1 mutants and characterisation
of their signalling ability
A panel of human TNFR1 mutants was generated in the
pcDNA3.1 vector (Fig. 1B). They were designed to delete largeportions of TNFR1 cytoplasmic C-terminus or to disrupt
speciﬁc C-terminal domains. NF-jB activation by the TNFR1
mutants was assessed by luciferase reporter assay of transiently
transfected Eli-BL cells (Fig. 2A), a B-cell line, which had a
low endogenous response to TNFa, compared with other cell
lines tested (data not shown). Eli-BL cells were co-transfected
with each TNFR1 construct or with empty vector and NF-jB
luciferase reporter plasmid, split into two, and 16 h later, one
half stimulated with TNFa and the other mock stimulated.
After 8 h incubation, the cells were harvested and assayed for
luciferase activity.
Fig. 3. Expression of TNFR1 constructs. DG75 cells were transfected
with 1 lg EGFP-N1 and 10 lg empty vector, pcDNA3.1 or an ex-
pression vector for TNFR1 Wt, TNFR1 D218 or TNFR1 AA. Ex-
pression was investigated by ﬂow cytometry with an anti-TNFR1
antibody or irrelevant IgG1 antibody and a PE-conjugated secondary
Fab fragments. Results are shown as dot plots against anti-TNFR1-PE
or isotype antibody-PE ﬂuorescence against EGFP ﬂuorescence and
are representatives of three independent experiments. The m.f.i of
staining for the transfected cell gate is shown in the top-right hand
corner of the dot plot. Untransfected cells and TNFR1 D218 trans-
fected cells stained with isotype antibody are shown for comparison.
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fold increase in NF-jB activity over that detected in the un-
stimulated control transfection (Fig 2A). Transfection of
TNFR1 Wt resulted in a 4.5-fold induction of NF-jB activa-
tion, in response to TNFa. Removal or mutation of the death
domain (D218, AA and DAA) resulted in no activation of NF-
jB. Removal of the FAN-binding domain (DFAN) had no
eﬀect on induction of NF-jB, compared to Wt. The TNFR1
mutants D218 and AA, were selected to test as dominant-
negative mutants of TNFR1 signalling, because of their in-
ability to activate NF-jB.
3.2. Ability of TNFR1 mutants to inhibit wt TNFR1 NF-jB
signalling
The eﬀectiveness of the TNFR1 D218 and AA constructs to
inhibit wild type receptor NF-jB signalling was compared,
revealing signiﬁcant diﬀerences between the two mutants
(Fig. 2B). Fig. 2B shows that co-transfection of the
TNFR1D218 deletion mutant inhibits wild type TNFR1 sig-
nalling much more eﬀectively than the point mutant, TNFR1
AA. In the absence of TNFa, increasing amounts of both
constructs had little eﬀect on the basal level of NF-jB acti-
vation. Addition of TNFa to cells transfected with Wt TNFR1
alone resulted in a 5-fold increase in NF-jB activity. Trans-
fection with increasing amounts of TNFR1 D218 resulted in a
marked decrease of TNFa-induced NF-jB activation. 6 lg of
TNFR1 D218 was suﬃcient to reduce the NF-jB activity to
basal levels. Transfection with increasing amounts of TNFR1
AA resulted in a less marked decrease of TNFa-induced NF-
jB activation. 12 lg of TNFR1 AA was not suﬃcient to re-
duce the NF-jB activity to the basal level and resulted in only
a 45% reduction in the maximal activity.
In addition, 12 lg of either TNFR1 D218 or AA was unable
to inhibit NF-jB activation by co-transfection of a constitu-
tively active viral TNFR1 mimic encoded by Epstein–Barr
virus, the latent membrane protein-1 (data not shown). This
demonstrated that the dominant-negative eﬀect of the TNFR1
mutants was speciﬁc to TNFa-induced signalling. These data
demonstrate that a speciﬁc TNFR1 dominant negative can be
generated by mutation of the adapter protein-binding do-
mains. However, deletion of the TNFR1 C-terminus generated
a more eﬃcient dominant negative than disruption of the DD
by the introduction of point mutations.
3.3. TNFR1 D218 cell surface expression levels are much higher
than TNFR1 Wt or AA
We sought to identify the mechanism for the diﬀerence be-
tween the TNFR1 D218 and TNFR1 AA dominant negatives.
To test the hypothesis that diﬀerences in expression levels were
responsible, expression studies were performed in two cell
lines. One cell line was Eli-BL, the same line used for the
analysis of NF-jB activation. We also used a highly trans-
fectable DG75 B-cell line that was unsuitable for the signalling
assays because it contains a high level of constitutive NF-jB
activity but which allowed a more sensitive analysis of TNFR1
expression. The expression of TNFR1 constructs on the cell
surface of viable transfected cells was measured by ﬂow cy-
tometry (Fig. 3 and Table 1) of cells stained with a mouse
monoclonal antibody against human TNFR1 and a PE-con-
jugated secondary antibody. Transfected cells were indicated
by the expression of GFP. Control non-transfected cells, cells
transfected with empty vector and GFP and cells transfectedwith TNFR1 D218 stained with an isotype control antibody
were also analysed in parallel.
The average mean ﬂuorescence intensities and standard er-
rors of TNFR1 staining of the transfected cell population are
shown in Table 1. There was a diﬀerence between the levels of
transfected TNFR1 expressed at the cell surface in both cell
types (Table 1). However, more expression of TNFR1 Wt
could be seen in DG75 cells. The basal level of TNFR1
staining (pcDNA3.1) was the same as that obtained using an
irrelevant isotype control antibody. This indicates that both
cell types express either no TNFR1 or levels below the limit of
detection. In both cell types, TNFR1 D218 was extremely
highly expressed, whereas TNFR1 Wt and AA expression was
lower generally, but still detectable. Higher levels of TNFR1
D218 were also detected by ﬂuorescence microscopy of ﬁxed
and stained cells (data not shown). A proportion of TNFR1
construct transfected cells showed no increase in TNFR1
staining above basal levels. This may reﬂect TNFR1 levels
Table 1
Cell surface expression of TNFR1 constructs in transfected DG75 and
Eli-BL cells
Construct TNFR1 staining in
DG75 cells
(average m.f.i. S.E.M.)
TNFR1 staining in
Eli-BL cells
(average m.f.i.S.E.M.)
pcDNA3.1 18 1 13 1
TNFR1 Wt 32 2 24 2
TNFR1 D218 325 34 508 215
TNFR1 D325 84 13 ND
TNFR1 AA 46 1 30 3
TNFR1 DFAN 50 2 ND
TNFR1 DAA 32 5 ND
TNFR1 D403 72 6 ND
TNFR1 D413 38 4 ND
TNFR1 D424 33 2 ND
The average mean ﬂuorescence intensity of TNFR1 staining of the
transfected (GFP positive) population for pcDNA3.1empty vector and
TNFR1 transfections from three independent experiments. TNFR1
D218 transfected cells were also stained with an isotype IgG1 antibody
as a control (average m.f.i. 19 3 and 10 1 for DG75 and Eli-BL,
respectively). ND, not done.
Fig. 4. NF-jB activation by the TNFR1 D403, D413 and D424 deletion
mutants. Eli-BL cells were transiently transfected with 3 lg NF-jB
luciferase reporter, 2 lg EGFP-N1and 6 lg of each construct.
Transfections were split into two and 16 h post-transfection one half
was mock stimulated and the other stimulated with 10 ng/ml TNFa.
After 8 h, luciferase activity was assayed. The results are shown as
fold-induction of NF-jB activity, calculated by division of the raw
value from the TNFa-stimulated well by the mock stimulated well, for
each transfection. The results are means and standard error of three
independent experiments.
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majority of TNFR1 was localised internally. There were no
diﬀerences in cell viability between the transfections. The in-
hibition of Wt TNFR1 signalling observed in Fig. 2B corre-
lates with the increased cell surface expression of the
C-terminal truncation mutant TNFR1 D218, relative to the
point mutant TNFR1 AA observed in Fig. 3.
3.4. Negative regulation of cell surface expression by a
membrane proximal region of the TNFR1 cytoplasmic
C-terminus
A previous study identiﬁed a region of the DD responsible
for lipid raft localisation (aa 405 and 412) [18]. This region of
TNFR1 is also involved in localisation to the trans-Golgi (aa
403–426), and contains a putative acidic cluster (aa 406–410)
and a dileucine motif (aa 424–425) [19], sequences known to
aﬀect protein localisation. To examine whether this region
inﬂuenced TNFR1 cell surface expression, we constructed a
further three deletion mutants (TNFR1 D403, D413 and D424).
One deletion (D403) removed this entire region including both
the acidic cluster and the dileucine motif. The other deletions
(D413 and D424) removed only the dileucine motif (see Fig. 1).
First, the ability of TNFR1 D403, D413 and D424 to activate
NF-jB was assessed by luciferase reporter assay in transiently
transfected Eli-BL cells (Fig. 4). Addition of TNFa to the con-
trol transfection resulted in approximately a 1.5-fold activation
of NF-jB. The TNFR1 Wt transfection resulted in a 6-fold ac-
tivation of NF-jB. As expected, transfection of the C-terminal
deletion mutant TNFR1 D218 responded in a similar way to
control transfection. Deletion of the entire region involved in
lipid raft localisation (D403) abolished NF-jB activation.
Shorter deletions (D413 and D424), which retained the acidic
cluster (aa 406–410), were Wt in their activation of NF-jB.
Expression studies were performed, as before, in the DG75
cells. These cells allow a higher expression of TNFR1 Wt and
so permitted more careful analysis of expression of these subtle
mutations. DG75 cells were transiently transfected with all
TNFR1 constructs, including another deletion mutant (D325),
which was unable to activate NF-jB (data not shown). The
average mean ﬂuorescence intensities and standard errors of
TNFR1 staining of the transfected cell population are shownin Table 1. TNFR1 Wt expression resulted in a 1.8-fold in-
crease in the m.f.i. of the transfected (GFP positive) cell pop-
ulation. TNFR1 D218 expression was 22-fold higher than that
of TNFR1 Wt. Mutation or deletion of the FAN-binding and
death domains had little eﬀect on the cell surface expression of
TNFR1. Deletion of short sections of the TNFR1 extreme C-
terminus (D413 and D424) also had little eﬀect of TNFR1 cell
surface expression. Deletion of the recently identiﬁed trans-
Golgi localisation sequence (D403) and a shorter deletion of
the TNFR1 C-terminus (D325) resulted in a small but signiﬁ-
cant increase in TNFR1 cell surface expression (approximately
4 to 5-fold increase on Wt levels). A region negatively regu-
lating TNFR1 cell surface expression therefore maps to a se-
quence between amino acids 218 and 324.4. Discussion
TNFR1 signalling plays a critical role in innate immune
function and inﬂammation and has also shown to be impor-
tant for the growth of B-cell lymphoma cell lines [5,20]. This
study investigated the generation of an eﬃcient dominant-
negative TNFR1 mutant by disruption of adapter protein-
binding domains. However, the removal of the full cytoplasmic
tail of TNFR1 (D218) was a more eﬃcient inhibitor of Wt
signalling, compared with the point mutant (AA). C-terminal
mutants had been described previously [7,21] and have been
shown to inhibit TNF-induced apoptosis. They were unable to
induce apoptosis in stable transfectants, in response to TNFa,
and they had some degree of dominant-negative ability be-
cause the levels of apoptosis were reduced relative to control
transfectants. The relative dominant-negative eﬃciency and
expression of TNFR1 point mutants versus deletion mutants
has not previously been determined.
The diﬀerent ability of TNFR1 mutants to inhibit Wt sig-
nalling correlated with TNFR1 surface expression. Removal of
a trans-Golgi localisation sequence [19] did result in a signiﬁ-
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extremely high levels observed for D218. Interestingly, aa 405–
413 within this same sequence was shown by another group to
be important for the localisation of TNFR1 to lipid rafts [18].
The equivalent mutants in our study indicate a requirement for
this sequence, which contains an acidic cluster, in NF-jB sig-
nalling. This is interesting in light of a recent report, which
showed that lipid rafts were essential for NF-jB signalling by
TNFR1 [22]. These results demonstrate that the amino acid
sequence responsible for the TNFR1 lipid raft localisation is
also essential for NF-jB activation.
Further expression studies showed that another TNFR1
mutant (D325) with amino acids 325–426 deleted was ex-
pressed at similar levels to D403. Therefore, a region of the
TNFR1 cytoplasmic C-terminus between amino acids 218 and
324 negatively regulates TNFR1 cell surface expression. This
region of TNFR1 is known to contain a number of phos-
phorylation sites [23] and phosphorylation of these sites can
relocalise TNFR1 [24]. It also contains a sequence that inter-
acts with the SH3 domain of Grb2 (aa 237–240) [12]. Inter-
estingly, the interaction of Grb2 with epidermal growth factor
receptor has a role in its internalisation by clathrin-coated pits
[25,26].
TNFR1 expression plays a major role in restricting TNFR1
function and the outcome of its signalling in response to TNF.
This report identiﬁes an important region, between amino
acids 218 and 324, with a major role in regulating TNFR1 cell
surface expression. Removal of this sequence greatly increased
TNFR1 cell surface expression and the dominant negative
eﬃciency of the resulting mutant.
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